Customize your JAMA Network experience by selecting one or more topics from the list below.
In the Research Letter entitled “Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019,”1 published in the May 28, 2019, issue of JAMA, a few columns were misaligned in the last 3 rows of the Table and pazopanib was misspelled in the Figure. Also, the first sentence of the second paragraph in the Results section should have read as follows: “Despite efforts to close the coverage gap between 2010 and 2019, mean expected out-of-pocket spending in 2019 benefit designs increased for 11 of 13 orally administered anticancer drugs available in both years…” This article was corrected online.
Misalignment in Table and Typographical Errors in Text and Figure. JAMA. 2019;322(2):174. doi:10.1001/jama.2019.8629
Coronavirus Resource Center
Create a personal account or sign in to: